CYSTIC FIBROSIS FOUNDATION (EIN 131930701) - Form 990 Financial Analysis & Trantor Score

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

1955

Legal Domicile

Principal Officer

MICHAEL P BOYLE MD

Phone

3019514422

Tax Period

2023-01-01 to 2023-12-31

CYSTIC FIBROSIS FOUNDATION, founded in 1955, is a major nonprofit in the Diseases & Disorders sector that reported $292.0M in total revenue in fiscal year 2023. Revenue grew 17% year-over-year, indicating healthy expansion. Expenses of $443.4M exceeded revenue, resulting in a 52% operating deficit.

Mission

TO CURE CYSTIC FIBROSIS (CF) AND TO PROVIDE ALL PEOPLE WITH CF THE (CONTINUED ON SCH O) OPPORTUNITY TO LEAD LONG, FULFILLING LIVES.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2023)

Revenue Breakdown

Contributions & Grants $86,607,373

Program Service Revenue $3,437,695

Investment Income $179,149,610

Other Revenue $22,821,602

TOTAL REVENUE $292,016,280

Expense Breakdown

Grants Paid $200,455,461

Salaries & Benefits $127,953,243

Fundraising Expenses $32,375,523

Program Expenses $361,812,102

Other Expenses $114,819,495

TOTAL EXPENSES $443,404,599

Year-over-Year Comparison

	2023	2022	Change
Revenue	$292,016,280	$248,630,352	+0.2%
Expenses	$443,404,599	$396,664,114	+0.1%
Net Income	$-151,388,319	$-148,033,762	+0.0%

Key Indicators

✓ Grants to Organizations ✓ Grants to Individuals ✓ Lobbying ✗ Political Activity ✓ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

847

Volunteers

53389

Governance Policies

✓ Conflict of Interest Policy

✓ Whistleblower Policy

✓ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

✗ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✓ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

$2,791,966

Total Directors

$1,472,782

Key Employees

$4,349,909

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
LOUIS A DEFALCO	VICE CHAIR	5.00	Director	$0	$0	$0
CAROLE B GRIEGO MD	TRUSTEE	3.00	Director	$0	$0	$0
KATE O'DONNELL	TRUSTEE	3.00	Director	$0	$0	$0
DODZIE SOGAH PHD	TRUSTEE	3.00	Director	$0	$0	$0
DAVID A MOUNT	TREASURER	3.00	Director	$0	$0	$0
ROBERT H NIEHAUS	VICE CHAIR	5.00	Director	$0	$0	$0
ERIC R OLSON PHD	VICE CHAIR	5.00	Director	$0	$0	$0
DOMINIC J CARUSO	TRUSTEE	3.00	Director	$0	$0	$0
PAUL A MOTENKO	TRUSTEE	3.00	Director	$0	$0	$0
TERESA L ELDER	VICE CHAIR	5.00	Director	$0	$0	$0
ERIC SCHNEIDER MD	TRUSTEE	3.00	Director	$0	$0	$0
STEVEN SHAK MD	TRUSTEE	3.00	Director	$0	$0	$0
JOHN S WEINBERG	EXECUTIVE VICE CHAIR	5.00	Director	$0	$0	$0
KC BRYAN WHITE	CHAIR	8.00	Director	$0	$0	$0
JESSICA H BOYD MD	TRUSTEE	3.00	Director	$0	$0	$0
MICHAEL P BOYLE MD	PRESIDENT & CEO	40.00	Officer Director	$1,372,546	$100,236	$1,472,782
IRENA BARISIC	EVP, CHIEF OPER/FIN OFFICER	40.00	Officer	$692,433	$50,204	$742,637
MICHAEL B CAVADEL	SVP, CHIEF LEGAL OFFICER	40.00	Officer	$494,693	$81,854	$576,547
JOHN C MAHLER JR	CHIEF INVESTMENT OFFICER	40.00	Key Emp	$2,747,771	$74,825	$2,822,596
BRUCE MARSHALL MD	EVP & CHIEF MEDICAL OFFICER	40.00	Key Emp	$741,926	$36,032	$777,958
JOHN P CLANCY MD	SVP, CLINICAL RESEARCH	40.00	Key Emp	$659,434	$89,921	$749,355
EARL A LEE	MANAGING DIRECTOR, INVESTMENTS	40.00	Highest	$1,114,424	$282,686	$1,397,110
ERIC KOEHRSEN	MANAGING DIRECTOR, INVESTMENTS	40.00	Highest	$949,505	$269,002	$1,218,507
ANDREW LEWIS	MANAGING DIRECTOR, INVESTMENTS	40.00	Highest	$1,268,837	$49,610	$1,318,447
GENTIANA S AROVAS	MANAGING DIRECTOR, INVESTMENTS	40.00	Highest	$541,296	$190,441	$731,737
ALBERT FARO	VP CLINICAL AFFAIRS	40.00	Highest	$517,875	$124,895	$642,770
PRESTON W CAMPBELL III MD	FORMER CEO & STRATEGIC ADVISOR	40.00		$241,993	$15,498	$257,491
WILLIAM SKACH MD	EVP & CHIEF SCIENTIFIC OFFICER	40.00		$277,714	$1,590	$279,304

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2024	No data	No data	No data	No data
2023	$292,016,280	$443,404,599	$4,885,921,122	$-151,388,319
2022	$248,630,352	$396,664,114	$4,735,058,992	$-148,033,762
2021	$417,237,551	$375,611,186	$5,691,109,976	$41,626,365
2020	$800,629,953	$381,380,991	$5,369,999,661	$419,248,962
2019	$605,778,425	$348,650,099	$4,476,511,082	$257,128,326
2018	$275,790,756	$337,912,568	$4,013,935,956	$-62,121,812

CYSTIC FIBROSIS FOUNDATION